Working… Menu

Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00273624
Recruitment Status : Terminated
First Posted : January 9, 2006
Last Update Posted : May 13, 2016
Information provided by (Responsible Party):
Claus Normann, University Hospital Freiburg

Brief Summary:
60 patients with major depression will be treated with 10 mg Olanzapine or Placebo for 2 weeks. In case of response (reduction of depressive symptoms)the study will be continued for further 60 days.

Condition or disease Intervention/treatment Phase
Therapy-resistant Depression Drug: Olanzapine Drug: Placebo Phase 3

Detailed Description:

The study is using a randomized double-blind, parallel-group, placebo-controlled design. 30 patients per treatment group will be included into the study and randomized to the treatment groups using a computer program. Psychotic features of depression will be excluded by a score of 2 or less in the PANSS subscales P1, P3 and P6. Treatment resistance as defined by history of non-response to two antidepressants from different classes at an acceptable dose and period is confirmed retrospectively. If possible, treatment compliance should be confirmed by plasma level examination. After informed consent, visit 1 is performed on day 0 (inclusion criteria, history, demographics, physical examination, vital signs, HAMD, MADRS, CGI, lab). Study medication is started on day 1, the antidepressive therapy is continued at stable dose until the end of the study. Patients will receive a double-blind therapy of either 10 mg/d olanzapine or placebo. Study visits will be performed on days 4, 7, and 14 (visits 2-4: vital signs, HAMD, MADRS, CGI, lab).

After 14 days, the patients will be classified as responders or non-responders. A responder is defined by a reduction of the initial HAM-D score of more than 50%. Study treatment will be stopped in non-responders and continued in a double-blind manner in responders for further 60 days. Thereafter, the the study medication is stopped and the patients are observed for further 14 days. Study visits will be performed every 14 days. This extension phase was added to examine if a prolonged treatment with olanzapine could ensure a sustained treatment effect. It should be excluded that olanzapine has a short-term tranquillizer-like effect or leads to unfavourable medium- to-long-term depressiogenic effects as observed with other neuroleptics used in depression ( e.g. fluspirilene). Moreover, withdrawal effects should be excluded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial
Study Start Date : June 2005
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: olanzapine
10 mg Olanzapine
Drug: Olanzapine
10 mg Olanzapin concurrent to antidepressive medication
Other Name: Zyprexa

Placebo Comparator: placebo
Drug: Placebo

Primary Outcome Measures :
  1. Hamilton-Depression-Scale- HAM-D [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. rate of remission (HAM-D less or equal 7) [ Time Frame: 14 days ]
  2. differences in HAM-D total scores [ Time Frame: 14 days ]
  3. differences in MADRS (Montgomery Asberg Depression Rating Scale)and CGI (Clinical Global Impression)scores [ Time Frame: 14 days ]
  4. predictive value of HAM-D subscales for treatment response use of comedication [ Time Frame: 14 days ]
  5. survival in study [ Time Frame: 14 days ]
  6. differences in rates of adverse events, weight [ Time Frame: 14 days ]
  7. differences in HAM-D scores and survival in extension phase [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • major depression without psychotic features
  • therapy resistance (2 courses of antidepressants from different classes for more than 3 weeks in adequate dose
  • HAM-D score greater/equal than 17
  • age 18-65

Exclusion Criteria:

  • bipolar disorder
  • active alcohol or illicit drug use
  • female with ineffective contraception
  • severe medical conditions, epilepsy
  • psychotic features

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00273624

Layout table for location information
Dept. of Psychiatry, University of Freiburg
Freiburg, Germany, 79104
Sponsors and Collaborators
University Hospital Freiburg
Layout table for investigator information
Principal Investigator: Claus Normann, MD Department of Psychiatry, University of Freiburg

Layout table for additonal information
Responsible Party: Claus Normann, Prof. Dr., University Hospital Freiburg Identifier: NCT00273624     History of Changes
Other Study ID Numbers: Olanzapine Augmentation
First Posted: January 9, 2006    Key Record Dates
Last Update Posted: May 13, 2016
Last Verified: May 2016
Keywords provided by Claus Normann, University Hospital Freiburg:
Therapy-resistant depression
add-on therapy depression
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents